fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Ranibizumab

All injection strengths: Limited Use (codes 651, 652, 653, 654)

Ranvu · DIN 02568950 · 10 mg/mL · injection, 0.165 mL pre-filled syringe (preservative-free)

Limited Use, Reason for Use code 651, 652, 653, 654 requiredApproved · checked October 5, 2026
StatusLimited Use, Reason for Use code 651, 652, 653, 654 required
Write on scriptone applicable Reason for Use code, 651 or 652 or 653 or 654 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 651, 652, 653, 654
Reason for Use code 651 For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a verteporfin PDT (Visudyne)-naive eye. Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections. Patients receiving concurrent administration with another anti-VEGF agent are not eligible for reimbursement. Treatment should be initiated with a loading phase of one injection per month for three consecutive months, followed by a maintenance phase. During the maintenance phase, patients should be monitored for best corrected visual acuity or continued disease activity. If there is clinical or diagnostic evidence of disease activity such as a loss of greater than 5 letters in visual acuity (Early Treatment Diabetic Retinopathy Score (ETDRS) chart or one Snellen line equivalent), ranibizumab may be administered. The interval between two doses should not be shorter than one month. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 652 For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and who have a hemoglobin A1c of less than 11 percent. Treatment to be given monthly and continued until maximum visual acuity is achieved, confirmed by stable visual acuity for three consecutive monthly assessments performed while on ranibizumab treatment. Thereafter patients should be monitored monthly for visual acuity. Treatment is resumed with monthly injections when monitoring indicates a loss of visual acuity due to DME and continued until stable visual acuity is reached again for three consecutive monthly assessments. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 653 For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Treatment to be given monthly and continued until maximum visual acuity is achieved, confirmed by stable visual acuity for three consecutive monthly assessments performed while on ranibizumab treatment. Thereafter patients should be monitored monthly for visual acuity. Treatment is resumed with monthly injections when monitoring indicates a loss of visual acuity due to macular edema secondary to retinal vein occlusion and continued until stable visual acuity is reached again for three consecutive monthly assessments. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 654 For the treatment of patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia. Treatment is initiated with a single intravitreal injection. Monitoring is recommended monthly for the first 2 months and at least every 3 months thereafter during the first year. If monitoring reveals signs of disease activity (e.g. reduced visual acuity and/or signs of lesion activity), further treatment is recommended at a frequency of 1 injection per month until no disease activity is seen. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Ranvu · DIN 02568950 Manufacturer: Apotex Inc.; listing date 2026-09-29 Health Canada: Approved since 2026-06-10 · brand RANVU · ATC S01LA04 RANIBIZUMAB · form Solution · route Intravitreal · ingredients RANIBIZUMAB 10 MG/ML · company Apotex inc · schedule Prescription, Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

Ranvu: Formulary list price $900.00 per unit (the source does not state the unit; exact figure $900.0000). What the ministry pays, not the patient.

Ministry pays: $900.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02568950)

Source record
DIN 02568950: Ranvu Raw flags: sec12=Y, sec3=Y Item: 920000833; group id 952; item number 2259; lccId 00372; manufacturer id APX Source form: Inj Sol-0.165mL Pref Syr (Preservative-Free); strength: 10mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $900.0000; ministry $900.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02568950 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107122
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02568950
Shortage record checked October 6, 2026
Health Canada lists this DIN as Approved since June 10, 2026 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: neovascular, visual impairment
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. AFLIBERCEPT · Limited Use, codes 729, 730, 731 (7), Limited Use, codes 694, 695 (2) • the treatment of neovascular (wet) age-related macular degeneration (AMD) PM: https://pdf.hres.ca/dpd_pm/00084821.PDF; date 2026-05-22; DIN 02535858; fetched 2026-09-10 Product monograph • the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) PM: https://pdf.hres.ca/dpd_pm/00084821.PDF; date 2026-05-22; DIN 02535858; fetched 2026-09-10 Product monograph • the treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) PM: https://pdf.hres.ca/dpd_pm/00084821.PDF; date 2026-05-22; DIN 02535858; fetched 2026-09-10 Product monograph BROLUCIZUMAB · Limited Use, codes 620, 648 1 INDICATIONS BEOVU® (brolucizumab injection) is indicated for: • The treatment of neovascular (wet) age-related macular degeneration (AMD). PM: https://pdf.hres.ca/dpd_pm/00077080.PDF; date Mar 12, 2020; DIN 02496976; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 Indications MELVIZO (ranibizumab injection) is indicated for: • the treatment of neovascular (wet) age-related macular degeneration (AMD). • the treatment of visual impairment due to diabetic macular edema (DME). • the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO). • the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM). • the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post- inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy. Indications have been granted on the basis of similarity between MELVIZO and the reference biologic drug Lucentis. 1.1 Pediatrics Health Canada has not authorized MELVIZO for pediatric use due to insufficient data on safety and efficacy in this sub-population. Limited data from 5 adolescent patients aged 13 to 17 years with visual impairment due to CNV are available. 1.2 Geriatrics Geriatrics (≥ 65 years of … https://pdf.hres.ca/dpd_pm/00082902.PDF PM date: November 7, 2025 Source product: MELVIZO; DIN 02525852; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.